This week, we added to 2 portfolio positions amid market weakness.
We believe the company will ramp production and continue to sign new pharmaceutical partners.
Still, we believe the company is trending in the right direction.
Slight increase in EPS is expected.
Oil company's earnings beat estimates, but revenue down.
We view temporary pullbacks as chances to buy.
The company has met or beat profit expectations in seven of the past eight quarters.
This will improve our average cost basis in the retailer.
But production was in line and it is generating free cash flow.
Consensus calls for revenue to climb.